Bipartisan lawmakers urge FDA to close peptide import loophole exploited for counterfeit obesity drug

Source Summary

A bipartisan group of lawmakers is calling on the FDA to close a regulatory loophole that allows unauthorized imports of counterfeit retatrutide, an investigational obesity medication developed by Eli Lilly. The lawmakers seek to prevent the importation of knockoff versions of the drug through this gap in federal oversight.

Why it matters

Closing this loophole would strengthen FDA oversight of drug imports and protect consumers from potentially unsafe counterfeit medications.

Read the Source

• STAT News ↗